Intersect ENT (Intersect ENT) Market Cap : $954.9 Mil (As of May. 06, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Intersect ENT Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Intersect ENT's share price for the quarter that ended in Mar. 2022 was $28.01. Intersect ENT's Shares Outstanding (EOP) for the quarter that ended in Mar. 2022 was 33.8 Mil. Therefore, Intersect ENT's market cap for the quarter that ended in Mar. 2022 was $947.0 Mil.

Intersect ENT's quarterly market cap increased from Sep. 2021 ($910.0 Mil) to Dec. 2021 ($918.7 Mil) and increased from Dec. 2021 ($918.7 Mil) to Mar. 2022 ($947.0 Mil).

Intersect ENT's annual market cap declined from Dec. 2019 ($802.7 Mil) to Dec. 2020 ($754.2 Mil) but then increased from Dec. 2020 ($754.2 Mil) to Dec. 2021 ($918.7 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Intersect ENT's Enterprise Value for Today is $1,061.8 Mil.

Intersect ENT Market Cap Historical Data

The historical data trend for Intersect ENT's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intersect ENT Market Cap Chart

Intersect ENT Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Market Cap

Get a 7-Day Free Trial

961.57

866.39

802.65

754.23

918.74

Intersect ENT Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Market Cap	Get a 7-Day Free Trial															691.88	568.43	909.98	918.74	947.02

Competitive Comparison of Intersect ENT's Market Cap

For the Medical Devices subindustry, Intersect ENT's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intersect ENT's Market Cap Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Intersect ENT's Market Cap distribution charts can be found below:

* The bar in red indicates where Intersect ENT's Market Cap falls into.

Intersect ENT Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Intersect ENT's Market Cap for the fiscal year that ended in Dec. 2021 is calculated as

Market Cap (A: Dec. 2021 )	=	Share Price (A: Dec. 2021 )	*	Shares Outstanding (EOP) (A: Dec. 2021 )
	=	$27.31	*	33.641
	=	$918.7

Intersect ENT's Market Cap for the quarter that ended in Mar. 2022 is calculated as

Market Cap (Q: Mar. 2022 )	=	Share Price (Q: Mar. 2022 )	*	Shares Outstanding (EOP) (Q: Mar. 2022 )
	=	$28.01	*	33.81
	=	$947.0

Intersect ENT (NAS:XENT) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Intersect ENT Market Cap Related Terms

Thank you for viewing the detailed overview of Intersect ENT's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Intersect ENT (Intersect ENT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intersect ENT Inc (NAS:XENT) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

1555 Adams Drive, Menlo Park, CA, USA, 94025

Website

https://www.intersectent.com

Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.

Executives

Elisabeth Sandoval	director	C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Neil A Hattangadi	director	1555 ADAMS DRIVE MENLO PARK CA 94025
Reyna M Fernandez	officer: Chief Human Resource Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Patrick A Broderick	officer: EVP, GC & Corporate Secretary	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Thomas A. West	director, officer: President and CEO	C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Richard A Meier	officer: EVP & Chief Financial Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Binney Robert H Jr	officer: Vice President, Sales	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Susan P Stimson	officer: Vice President, Marketing	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Lisa D Earnhardt	director, officer: See Remarks	1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Aaron Lehman	officer: General Counsel	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeryl L Hilleman	officer: Chief Financial Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Christine R Kowalski	officer: Chief Operations Officer	C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mead Dana G Jr.	director	2750 SAND HILL ROAD, MENLO PARK CA 94025
Richard E Kaufman	officer: See Remarks	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Gwen R. Carscadden	officer: Chief People Officer	C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025